在高新技术产业的快速发展中,标准必要专利(SEP)成为推动技术创新和产业升级的关键因素。然而,SEP保护过程中可能遭遇垄断风险、标准必要性界限模糊和司法裁决标准不一等诸多挑战。基于此,亟需构建一个更加健全的SEP保护体系。可以通过...在高新技术产业的快速发展中,标准必要专利(SEP)成为推动技术创新和产业升级的关键因素。然而,SEP保护过程中可能遭遇垄断风险、标准必要性界限模糊和司法裁决标准不一等诸多挑战。基于此,亟需构建一个更加健全的SEP保护体系。可以通过明确垄断行为责任规制、建立公正的SEP标准必要性评估机制以及完善司法裁决规则等方式,减少SEP诉讼纠纷并防止SEP权利人滥用市场支配地位。此外,还应重视否定默示许可制度,尝试建立高新技术产业SEP专属禁令救济机制,以期达到维持SEP权利人和潜在实施人之间的利益平衡,同时注重保护公共利益。SEP保护体系的完善有利于推动高新技术产业的发展,并为其创造一个更加公平和良好的知识产权保护环境,从而激励创新,促进我国高新技术产业的健康发展,提升我国专利的全球竞争力。In the rapid development of high-tech industries, Standard Essential Patents (SEP) have become a key factor in driving technological innovation and industrial upgrading. However, the protection process of SEP may encounter numerous challenges, such as the risk of monopolistic practices, the ambiguity of the boundaries of standard-essentiality, and the inconsistency in judicial decision-making criteria. In light of this, there is an urgent need to establish a more robust system for the protection of Standard Essential Patents (SEP). This can be achieved through clarifying the regulation of responsibilities for monopolistic conduct, establishing a fair mechanism for assessing the standard-essentiality of SEP, and refining the rules for judicial decisions. These measures aim to reduce disputes over SEP litigation and prevent SEP holders from abusing their market-dominant positions. Furthermore, attention should be given to the negation of the implied license system, and efforts should be made to establish an exclusive injunction relief mechanism for SEPs in the high-tech industry. This is aimed at maintaining a balance of interests between SEP right holders and potential implementers, while also focusing on the protection of the public interest. The improvement of the SEP protection system is conducive to promoting the development of the high-tech industry and creating a more equitable and favorable environment for intellectual property rights protection. This, in turn, stimulates innovation and fosters the healthy development of China’s high-tech industry, enhancing the global competitiveness of China’s patents.展开更多
目的评估放疗联合替西罗莫司治疗方案在中晚期肾癌临床治疗中的疗效及安全性。方法将入选的73例中晚期肾癌患者采用随机数字表法分为两组,即对照组(36例)和治疗组(37例)。对照组采用放射治疗,照射剂量为200 c Gy/d,每周照射5 d,5周为1...目的评估放疗联合替西罗莫司治疗方案在中晚期肾癌临床治疗中的疗效及安全性。方法将入选的73例中晚期肾癌患者采用随机数字表法分为两组,即对照组(36例)和治疗组(37例)。对照组采用放射治疗,照射剂量为200 c Gy/d,每周照射5 d,5周为1个治疗周期,每个周期照射总剂量为5000 c Gy;治疗组患者在放射治疗的基础上,配合250 m L氯化钠溶液给予静脉滴注替西罗莫司治疗,20毫克/次,静脉滴注60min,每周2次,5周为一个治疗周期。在治疗前、完成一个治疗周期后,分别对患者的临床疗效、生活质量进行评估,检测患者血清肿瘤标志物水平的变化,同时观察并记录两组患者治疗过程中出现的毒性作用。结果完成一个周期治疗后,与对照组患者相比,治疗组患者的治疗显效率为32.43%、治疗有效率为72.97%,均显著高于对照组患者的13.89%和41.67%(P<0.05);治疗组患者的躯体功能、角色功能、情感功能、认知功能、社会功能等功能项目的评分在接受治疗后均明显改善,且改善程度明显优于对照组患者(P<0.05);治疗后,治疗组患者血清中神经元特异性烯醇化酶、糖类癌抗原125、癌胚抗原、铁蛋白、β2-微球蛋白等肿瘤标志物的水平明显降低,且显著低于对照组患者的相应指标(P<0.05);此外,在治疗过程中,两组患者均有数例出现中度或重度不良反应,但治疗组患者中出现疲弱、困倦、脱发、恶心呕吐、关节疼痛、肝损伤、白细胞减少症等不良反应的发生率均显著低于对照组患者(P<0.05)。结论放疗联合替西罗莫司的治疗方案用于中晚期肾癌的临床治疗,在改善患者病情、提高患者生活质量、改善患者血清肿瘤标志物水平等方面都能够取得良好效果,而且不良反应发生率较低。展开更多
文摘在高新技术产业的快速发展中,标准必要专利(SEP)成为推动技术创新和产业升级的关键因素。然而,SEP保护过程中可能遭遇垄断风险、标准必要性界限模糊和司法裁决标准不一等诸多挑战。基于此,亟需构建一个更加健全的SEP保护体系。可以通过明确垄断行为责任规制、建立公正的SEP标准必要性评估机制以及完善司法裁决规则等方式,减少SEP诉讼纠纷并防止SEP权利人滥用市场支配地位。此外,还应重视否定默示许可制度,尝试建立高新技术产业SEP专属禁令救济机制,以期达到维持SEP权利人和潜在实施人之间的利益平衡,同时注重保护公共利益。SEP保护体系的完善有利于推动高新技术产业的发展,并为其创造一个更加公平和良好的知识产权保护环境,从而激励创新,促进我国高新技术产业的健康发展,提升我国专利的全球竞争力。In the rapid development of high-tech industries, Standard Essential Patents (SEP) have become a key factor in driving technological innovation and industrial upgrading. However, the protection process of SEP may encounter numerous challenges, such as the risk of monopolistic practices, the ambiguity of the boundaries of standard-essentiality, and the inconsistency in judicial decision-making criteria. In light of this, there is an urgent need to establish a more robust system for the protection of Standard Essential Patents (SEP). This can be achieved through clarifying the regulation of responsibilities for monopolistic conduct, establishing a fair mechanism for assessing the standard-essentiality of SEP, and refining the rules for judicial decisions. These measures aim to reduce disputes over SEP litigation and prevent SEP holders from abusing their market-dominant positions. Furthermore, attention should be given to the negation of the implied license system, and efforts should be made to establish an exclusive injunction relief mechanism for SEPs in the high-tech industry. This is aimed at maintaining a balance of interests between SEP right holders and potential implementers, while also focusing on the protection of the public interest. The improvement of the SEP protection system is conducive to promoting the development of the high-tech industry and creating a more equitable and favorable environment for intellectual property rights protection. This, in turn, stimulates innovation and fosters the healthy development of China’s high-tech industry, enhancing the global competitiveness of China’s patents.
文摘目的评估放疗联合替西罗莫司治疗方案在中晚期肾癌临床治疗中的疗效及安全性。方法将入选的73例中晚期肾癌患者采用随机数字表法分为两组,即对照组(36例)和治疗组(37例)。对照组采用放射治疗,照射剂量为200 c Gy/d,每周照射5 d,5周为1个治疗周期,每个周期照射总剂量为5000 c Gy;治疗组患者在放射治疗的基础上,配合250 m L氯化钠溶液给予静脉滴注替西罗莫司治疗,20毫克/次,静脉滴注60min,每周2次,5周为一个治疗周期。在治疗前、完成一个治疗周期后,分别对患者的临床疗效、生活质量进行评估,检测患者血清肿瘤标志物水平的变化,同时观察并记录两组患者治疗过程中出现的毒性作用。结果完成一个周期治疗后,与对照组患者相比,治疗组患者的治疗显效率为32.43%、治疗有效率为72.97%,均显著高于对照组患者的13.89%和41.67%(P<0.05);治疗组患者的躯体功能、角色功能、情感功能、认知功能、社会功能等功能项目的评分在接受治疗后均明显改善,且改善程度明显优于对照组患者(P<0.05);治疗后,治疗组患者血清中神经元特异性烯醇化酶、糖类癌抗原125、癌胚抗原、铁蛋白、β2-微球蛋白等肿瘤标志物的水平明显降低,且显著低于对照组患者的相应指标(P<0.05);此外,在治疗过程中,两组患者均有数例出现中度或重度不良反应,但治疗组患者中出现疲弱、困倦、脱发、恶心呕吐、关节疼痛、肝损伤、白细胞减少症等不良反应的发生率均显著低于对照组患者(P<0.05)。结论放疗联合替西罗莫司的治疗方案用于中晚期肾癌的临床治疗,在改善患者病情、提高患者生活质量、改善患者血清肿瘤标志物水平等方面都能够取得良好效果,而且不良反应发生率较低。
